Moreover, several preclinical models including melanoma, breast and CRC have demonstrated that anti-MARCO monoclonal antibodies not only reduce tumor volumes, but also appear to convert MARCO-expressing TAMs from an M2 to an M1 phenotype while also reducing Treg levels [420]. Here, MARCO is linked to melanoma.